多西他赛顺铂联合同步放疗治疗Ⅲ期非小细胞肺癌的临床疗效及安全性  

Clinical efficacy and safety of docetaxel plus cisplatin combined with concurrent radiation in the treatment of stage Ⅲ non-small cell lung cancer

作　　者：柯春林[1] 罗荣刚[1] 林剑波[1] 刘波[1] 李旭[1] 赖繁彩[1] 

机构地区：[1]福建医科大学附属第一医院胸外科,福州350005

出　　处：《中国临床药理学杂志》2015年第21期2102-2104,共3页The Chinese Journal of Clinical Pharmacology

基　　金：2015年福建省科技项目计划基金资助项目(2015Y0015)

摘　　要：目的探讨多西他赛、顺铂化疗联合同步放疗治疗Ⅲ期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法入选Ⅲ期NSCLC患者20例为研究对象。患者入组后,第1天,静脉滴注多西他赛20 mg·m-2,顺铂30 mg·m-2。在放射治疗开始时同步进行化疗,每周1次,共3周;放疗剂量为每次2 Gy,每周5次,总剂量为30 Gy。放疗结束后2周进行NSCLC临床分期评估和手术治疗。评价患者的临床缓解率、手术切除率及术后生存时间。结果 20例患者中完成3周期的化疗和30 Gy放疗者18例,18例患者中完全缓解2例,部分缓解6例,稳定8例,进展2例,客观缓解率44.4%。11例患者接受了手术治疗,手术完整切除者9例,1例患者肿瘤与侵犯大血管,1例发生广泛胸膜转移未能手术切除,手术切除率为81.8%。患者的中位生存时间为18.5个月,其中,新辅助放化疗后接受手术治疗组中位生存时间为22.5个月,未能接受手术组为10.1个月;手术组中位生存时间显著高于未手术组(P<0.05)。2例患者放化疗过程中出现严重不良反应而退出本研究。结论多西他赛顺铂方案联合同步放疗可提高Ⅲ期非小细胞肺癌手术切除率。Objective To investigate the clinical effects of docetaxel plus cisplatin combined with concurrent radiation in the treatment of stageⅢ non-small cell lung cancer （ NSCLC ） .Methods Twenty patients with stageⅢNSCLC were recruited.Patients were treated with docetaxel 20 mg· m-2 intravenous drop infusion plus cisplatin 30 mg· m-2 intravenous drop infusion on day 1.At the same time, the patients also received radiation with 2 Gy qd for 5 times per week with the total dosage of 30 Gy.Two weeks after the chemoradiation, patients received the clinical stage evaluation and surgery. The clinical efficacy, surgical resection rate and survival time were evaluated.Results Eighteen cases finished the 3 cycle chemoradiation. For the 18 subjects, 2 cases achieved complete response, 6 achieved partial response, 2 achieved sta-ble disease and 2 achieved progress disease with the objective response rate of 44.4%.Of the 18 cases, 11 patients received operation, with the completed removal rate of 81.8%, two patients with pleural metastasis or tumor invasion of the large vessel were not given complete removal.The median survivals were 22.5 months and 10.1 months in the operation group and non-operation group with statistical difference（ P〈0.05）.Two cases drop out of the trial for severe adverse event.Conclusion Docetaxel plus cisplatin combined with concurrent radiation can improve the operation rate for stage Ⅲnon-small cell lung cancer.

关 键 词：新辅助化疗 非小细胞肺癌 多西他赛 顺铂 放化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]